NewsRx

Search our medical news database

Blood Safety

SARS virus inactivated with Intercept Blood System

Published in TB and Outbreaks Week, August 19th, 2003

Cerus Corporation (CERS) announced study results demonstrating that the Intercept Blood System for platelets and red blood cells inactivates the causative agent of Severe Acute Respiratory Syndrome (SARS).

The Intercept Blood System for platelets, approved for commercial use in Europe, is a blood safety technology that protects patients by reducing the risk of transfusion-transmitted diseases. Cerus is developing the Intercept Blood System for use with platelets, plasma, and red blood cells in collaboration with subsidiaries of Baxter International, Inc.

"We are pleased to report these inactivation results as the launch of Intercept platelets gets...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook